Price-beating products for major markets
Xbrane’s first product offering will be Spherotide: the first generic formulation of the prostate cancer GnRH agonist triptorelin (sales $446m) made by Xbrane’s Italian subsidiary. First sales are likely to be in Iran from 2017. Bigger sales could be generated by a biosimilar of Lucentis, Xlucane, produced at a low cost using a proprietary process. Xlucane might be marketed in the US from 2021, a year after patent expiry, and from patent expiry in Europe in 2022. Lucentis sales worldwide are about $3.6bn.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.